Does the linked 25.07 matrix prove current v4.0 support is absent?

No. It documents a named historical revision. Ask for the currently supported product release, regional eCTD v4.0 profile and a representative report. Unknown current support stays unresolved.

Is CA-eCTD v4.0 in a set name the same as ICH eCTD 4.0?

Not necessarily. The linked matrix pairs that set name with Schema 2.2. Record the eCTD format version separately from the regional validation-set revision and confirm their mapping.

Can FAST validation replace full release checks?

The 25.07 document describes FAST sets as reduced criteria. Verify which applicable checks they omit and run the intended full release configuration; do not treat a reduced-check pass as equivalent.

Is EURSvalidator free?

The current primary page describes regional subscriptions and a personalized offer. Obtain current licensing and set-package terms; do not substitute agency-use claims for sponsor pricing.

Comparison/Updated October 2026

Assyro Validation vs EXTEDO EURSvalidator

Compare the actual licensed set and complete report, keeping rule-set versions separate from the eCTD format version.

Assyro Validation

by Assyro AI

Cloud validation of supported eCTD sequences from Assyro or another publisher.

External packagesSupported regional criteriaCloud workflowRelated eCTD

EXTEDO EURSvalidator

Standalone technical validator with regional validation-set subscriptions

Regional set subscriptions for technical submission checks, with configuration and reporting choices.

Regional subscriptionsNeeS/veterinary setsSet selectionFull/FAST distinction

The verdict

Evaluate Assyro Validation for its approved FDA, Health Canada and EMA centralised eCTD scope and a shared cloud workflow. Evaluate EURSvalidator when its demonstrated regional, NeeS or veterinary sets meet requirements beyond that scope. EXTEDO's currently linked support matrix explicitly describes EURS 8.0 / EURSvalidator 25.07; it is evidence for that revision, not proof of the latest product's complete scope. Confirm current v4.0 availability in a dated proposal and sample report rather than inferring absence from an older set list.

Individually written by Assyro AI, a compared vendor. Current product page and currently linked ten-page EURS 8.0 / EURSvalidator 25.07 matrix reopened October 13, 2026. The PDF's actual title controls its revision scope; availability does not make it a current release matrix. No executed cross-validator benchmark is claimed.

A validation profile needs four separate identifiers

Write down software release, eCTD format, regional implementation and criteria/set revision before comparing results.

Qualification questions
Requirement	Assyro	EURSvalidator
Supported external package	Approved regional profile	Current licensed set
v4.0	FDA; EMA initial MAA	Require current release-specific proof
NeeS/veterinary	Outside approved scope	Qualify listed sets and licence
Complete checks	Retain enabled configuration	Confirm full set versus FAST

Supported external package
Assyro
Approved regional profile
EURSvalidator
Current licensed set
v4.0
Assyro
FDA; EMA initial MAA
EURSvalidator
Require current release-specific proof
NeeS/veterinary
Assyro
Outside approved scope
EURSvalidator
Qualify listed sets and licence
Complete checks
Assyro
Retain enabled configuration
EURSvalidator
Confirm full set versus FAST

[1][2][3]

An old matrix and a current product promise answer different questions

The current product page establishes a regional-subscription offering. The named 25.07 document provides detailed behavior for that revision. Use both carefully, and leave newer profile availability open until the vendor supplies dated evidence.

Apply the same standard to Assyro. Supported v3.2.2 scope is FDA, Health Canada and EMA centralised; v4.0 is FDA and EMA initial MAA. The pilot must establish the required profile and operation within those boundaries.

[1][2][3]

Feature by feature

Published capabilities, related applications and evidence still to request.

Existing sequence validation
Assyro Validation
Supported external packages[3]
EURSvalidator
Standalone technical validation[1]
Regional scope
Assyro Validation
FDA, Health Canada, EMA centralised[3]
EURSvalidator
Licensed regional sets; confirm current matrix[1][2]
eCTD v4.0
Assyro Validation
FDA and EMA initial MAA scope[3]
EURSvalidator
Current release/profile evidence required[2]
NeeS/veterinary formats
Assyro Validation
Outside approved validation scope[3]
EURSvalidator
Sets listed in the revision-specific matrix[2]
Full versus reduced checks
Assyro Validation
Qualify enabled criteria and unsupported checks[3]
EURSvalidator
FAST sets use reduced criteria in the 25.07 document[2]
Commercial terms
Assyro Validation
Custom with unlimited users[5]
EURSvalidator
Regional subscriptions; personalized offer[1]

Assyro Validation and EXTEDO EURSvalidator: feature comparison
Capability	Assyro Validation	EURSvalidator
Existing sequence validation	Supported external packages[3]	Standalone technical validation[1]
Regional scope	FDA, Health Canada, EMA centralised[3]	Licensed regional sets; confirm current matrix[1][2]
eCTD v4.0	FDA and EMA initial MAA scope[3]	Current release/profile evidence required[2]
NeeS/veterinary formats	Outside approved validation scope[3]	Sets listed in the revision-specific matrix[2]
Full versus reduced checks	Qualify enabled criteria and unsupported checks[3]	FAST sets use reduced criteria in the 25.07 document[2]
Commercial terms	Custom with unlimited users[5]	Regional subscriptions; personalized offer[1]

Product details and recommendations reflect publicly available information and our own assessment as of October 2026, provided for comparison. EXTEDO EURSvalidator is a product of EXTEDO; trademarks belong to their respective owners.

Which one should you choose?

Choose Assyro Validation if

Your exact sequence profile is within approved Assyro validation scope.
Shared cloud findings review fits the release process.
You want to evaluate validation with separately scoped drafting and publishing.

Choose EURSvalidator if

Required regional, NeeS or veterinary sets are demonstrated and licensed.
A regional subscription fits the actual filing portfolio.
The report/configuration workflow passes your defect and repeatability sample.

The detailed comparison

What does the version number describe?

Assyro Validation

Keep format, regional implementation, criteria revision and software release in separate fields. Assyro's v4.0 scope is not a claim of every region's implementation.

EURSvalidator

The 25.07 matrix includes names such as CA-eCTD v4.0 with Schema 2.2. That set label is not evidence of ICH eCTD format 4.0. Ask for the complete format/implementation/profile mapping.

[2][3]

Did the validator run the complete intended checks?

Assyro Validation

Define expected findings from a known applicable defect and retain the enabled profile/configuration. Explain skipped or unsupported checks before release.

EURSvalidator

The support matrix describes FAST sets as reduced to minimal criteria and says automatic set selection does not apply to NeeS. Verify the selected full set and required manual choices; a fast report is not automatically a complete report.

[2]

Price the licensed sets and ongoing profile governance

List required countries, formats, users, deployment, reporting, updates and support. Obtain a dated current set matrix with the proposal and confirm restrictions on regional packages. Quote any required extensions separately.

Include configuration review, training, acceptance, discrepancy handling, report retention and update assessment on both sides. Compare the same intended release workflow; no matched quote supports a cost advantage.

[1][2][5]

Test profile selection and report completeness

Use a worksheet with input identity, selected profile, enabled checks, expected finding, observed result and disposition.

Version ambiguity

Present a regional set label that resembles a format version. Require the operator to identify both values correctly.

Full versus FAST

Use a defect outside a reduced set and reconcile why the full configuration should report it.

Manual selection

When NeeS is required, demonstrate the appropriate profile choice instead of assuming automatic selection.

Repeat and retain

Rerun an unchanged input, explain discrepancies and export a report with enough configuration evidence for independent review.

Where EURSvalidator is stronger

No tool wins on everything. Here is where EURSvalidator is the better choice today.

Explicit regional subscription structure can suit a defined multi-region filing portfolio.
Revision-specific documentation lists formats beyond Assyro's approved validation scope.
Published set-selection and reporting behavior gives buyers concrete configuration questions.

Adopting Assyro Validation

Compare reports on unchanged retained inputs before moving release reliance. A shorter findings list can reflect reduced checks or a different profile. Keep the prior validator available until unexplained discrepancies are resolved.

1Retain input identity, existing reports and selected sets/configuration.
2Map required format, regional implementation and criteria revisions.
3Run authorized valid/invalid samples in both configurations.
4Reconcile findings by criterion, file, severity and enabled check.
5Approve differences, release ownership, update review, retention and fallback.

Sources and evidence

Product documents establish published scope. Evaluation scenarios and recommendations are Assyro's analysis. Confirm availability, configuration and contract scope with each vendor.

EXTEDO EURSvalidator
Current technical validator, regional subscriptions and personalized-offer scope; checked October 13, 2026; no release displayed
EURS 8.0 / EURSvalidator 25.07 sets and functionality
Actual title identifies 8.0/25.07; pages 1–7 set/package matrix, page 8 automatic-selection/NeeS exception and reduced FAST sets; reopened October 13, 2026; not asserted as latest release
Assyro Validation product scope
Published product definition and capability scope; checked October 13, 2026; related applications require their own quoted scope
Assyro eCTD product scope
Published product definition and capability scope; checked October 13, 2026; related applications require their own quoted scope
Assyro pricing
Published custom pricing and unlimited users on every plan; checked October 13, 2026; no competitor price advantage inferred